Apararenone
Apararenone (INN) (developmental code name MT-3995) is a nonsteroidal antimineralocorticoid which is under development by Mitsubishi Tanabe Pharma for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis. It was also previously being developed for the treatment of hypertension, but development was discontinued for this indication. Apararenone acts as a highly selective antagonist of the mineralocorticoid receptor (Ki < 50 nM), the receptor for aldosterone. As of 2017, it is in phase II clinical trials.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Apararenone
Apararenone (INN) (developmental code name MT-3995) is a nonsteroidal antimineralocorticoid which is under development by Mitsubishi Tanabe Pharma for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis. It was also previously being developed for the treatment of hypertension, but development was discontinued for this indication. Apararenone acts as a highly selective antagonist of the mineralocorticoid receptor (Ki < 50 nM), the receptor for aldosterone. As of 2017, it is in phase II clinical trials.
has abstract
Apararenone (INN) (development ...... s in phase II clinical trials.
@en
CAS number
945966-46-1
ChEMBL
FDA UNII code
832663U2NB
PubChem
Link from a Wikipage to an external page
Wikipage page ID
54,193,852
page length (characters) of wiki page
Wikipage revision ID
992,853,384
Link from a Wikipage to another Wikipage
CAS number
ChEMBL
ChemSpiderID
28,663,572
IUPAC name
N-[4--2,2-dimethyl-3-oxo-1,4-benzoxazin-7-yl]methanesulfonamide
@en
PubChem
24,744,336
routes of administration
SMILES
CC1C
@en
StdInChIKey
AZNHWXAFPBYFGH-UHFFFAOYSA-N
@en
synonyms
MT-3995
@en
UNII
wikiPageUsesTemplate
comment
Apararenone (INN) (development ...... s in phase II clinical trials.
@en
label
Apararenone
@en